Design (Testphase)
Risk & Weakness
Kathy Donnelly: Liquid Movers Down
18
Findings
July 21, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Market filter active: the list shows 18 hits from US
Donnelly's sell/risk side (lifecycle trade approach): stocks with at least $20M in daily dollar volume that are down at least 5% today. When stocks sell off on this much liquidity, institutions are heading for the exit — a warning sign for holders, and for Donnelly the trigger to review exit rules. Mover threshold calibrated by Minnow Street.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(17)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth Minnow Street company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from -100 to +100 with a school-grade rank from A+ to F. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. A/A+ are the fundamentally strongest stocks in the universe.
- Institutions (Funds & Large Holders)
- Funds, pension plans, and asset managers - they move the big money and must disclose their US holdings quarterly. When the number of funds adding to a position rises, that is called institutional accumulation: the fuel behind major trends.
- Liquidity
- How easily a stock can be bought and sold without moving the price - measured by (dollar) volume. Illiquid stocks have wide spreads and jerky prices; that is why almost every scanner applies a minimum liquidity filter.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HYLN Hyliion Holdings Corp. | 08/11 | +90 % | — | Stage 2 | C +9 | 4 of 9 | 0.0 | Auto Parts | Uses AI | — | Consumer Cyclical | 3.60 $ | +231.5 % | +141.9 % | +248.9 % | −42.8 % | +44.0 % | 98 | 50 | 13.6 % | 15.8 % | 3.47 | — | 0.0 | — | — | — | — | -0.8 | -481.7 % | 6.3 % | 0.0 % | -25.2 % | -17.5 % | — | 95.3 % | +130.3 % | 0.0 % | 0.0 % | 21.4 | 25.2 % | 7.6 % | 2.0 (1) | |
| SLS Sellas Life Sciences Group Inc | 08/11 | +148 % | — | Stage 2 | C +5 | 3 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 12.50 $ | +140.6 % | +444.0 % | +436.3 % | −4.8 % | -5.0 % | 98 | 50 | 12.4 % | 11.1 % | 2.43 | — | 0.0 | — | — | — | — | -1.7 | 0.0 % | — | 0.0 % | -43.6 % | -25.5 % | — | 94.1 % | -100.0 % | 0.0 % | 0.0 % | 16.0 | 27.6 % | 32.4 % | 1.0 (3) |
| TWST Twist Bioscience Corp | 08/03 | +131 % | 54 5/22 | Stage 2 | D -16 | 4 of 9 | 6.0 | Diagnostics & Research | – | — | — | Healthcare | 87.50 $ | +168.0 % | +192.9 % | +158.6 % | −1.8 % | -23.3 % | 96 | 42 | 7.7 % | 7.8 % | 2.12 | — | 0.0 | 14.7 | 13.7 | — | — | -35.3 | -34.9 % | 52.1 % | -19.9 % | -18.2 % | -12.9 % | 0.21 | 67.3 % | +20.3 % | 0.0 % | 0.0 % | -0.1 | 123.8 % | 36.4 % | 1.3 (12) |
| ANAB AnaptysBio Inc | 08/05 | +114 % | 81 7/22 | Stage 2 | C -10 | 3 of 9 | 1.8 | Biotechnology | – | — | — | Healthcare | 50.30 $ | +83.9 % | +97.9 % | +284.4 % | −18.6 % | +45.9 % | 96 | 42 | 5.8 % | 5.3 % | 0.38 | — | 0.0 | 7.6 | 136.2 | 401.6 | — | 27.4 | -135.5 % | 44.6 % | -11.5 % | -114.6 % | 6.8 % | 21.76 | 3.9 % | +157.0 % | 0.0 % | 0.0 % | 1.7 | 104.2 % | 35.6 % | 1.2 (12) |
| PVLA Palvella Therapeutics, Inc | 08/13 | +73 % | 27 3/22 | Stage 2 | D -45 | 3 of 9 | 2.0 | Biotechnology | – | — | — | Healthcare | 124.10 $ | +13.4 % | +46.3 % | +476.0 % | −9.9 % | +68.6 % | 95 | 42 | 7.0 % | 6.4 % | — | — | 0.0 | — | 8.4 | — | — | 0.0 | — | — | 0.0 % | -34.3 % | -16.6 % | 0.00 | — | -100.0 % | 0.0 % | 0.0 % | 14.3 | 96.4 % | 16.4 % | — |
| TRVI Trevi Therapeutics Inc | 08/06 | +178 % | 55 5/22 | Stage 2 | D -47 | 3 of 9 | 2.6 | Biotechnology | – | — | — | Healthcare | 16.80 $ | +38.8 % | +43.6 % | +204.7 % | −0.9 % | +32.8 % | 93 | 42 | 6.1 % | 5.0 % | 1.00 | — | 0.0 | — | — | — | — | -4.9 | 0.0 % | — | 0.0 % | -33.6 % | -23.0 % | — | 95.8 % | — | 0.0 % | 0.0 % | 25.7 | 98.3 % | 11.2 % | 1.0 (8) |
| JBIO Jade Biosciences, Inc. | 08/12 | -21 % | 55 5/22 | Stage 2 | E -53 | 2 of 9 | 1.2 | Biotechnology | – | — | — | Healthcare | 19.70 $ | +42.4 % | +33.8 % | +121.9 % | −22.1 % | +122.4 % | 93 | 42 | 9.6 % | 9.1 % | — | — | 0.0 | — | 4.5 | — | — | 0.0 | — | — | 0.0 % | -89.2 % | -33.6 % | 0.00 | — | — | 0.0 % | 0.0 % | 18.0 | 84.8 % | 10.1 % | — |
| AVTX Avalo Therapeutics Inc | 08/06 | -33 % | 41 4/22 | Stage 3 | E -67 | 2 of 9 | 1.0 | Biotechnology | – | — | — | Healthcare | 18.20 $ | -1.8 % | +2.0 % | +279.1 % | −25.8 % | +151.4 % | 91 | 42 | 7.7 % | 7.4 % | 0.79 | — | 0.0 | 9,690.0 | — | — | — | -0.2 | — | -66,988.1 % | 0.0 % | -88.8 % | -41.5 % | — | — | -86.6 % | 0.0 % | 0.0 % | -10.4 | 76.6 % | 14.1 % | — |
| SPIR Spire Global Inc | 08/12 | +124 % | 85 10/29 | Stage 2 | D -21 | 4 of 9 | 0.6 | Specialty Business Services | Sells AI | — | — | Industrials | 11.00 $ | +132.5 % | +114.7 % | +76.8 % | −38.3 % | +30.6 % | 90 | 42 | 9.1 % | 11.1 % | 2.52 | 10.3 | 0.0 | 9.3 | 7.3 | — | — | 9.9 | — | 42.3 % | 77.1 % | 101.2 % | -27.2 % | 0.13 | — | -35.2 % | 0.0 % | 0.0 % | -8.1 | 39.9 % | 12.3 % | — |
| XRX Xerox Corp | 07/30 | -24 % | 60 7/29 | Stage 3 | D -27 | 4 of 9 | 0.4 | Business Equipment & Supplie | – | — | — | Industrials | 2.60 $ | +35.1 % | +31.2 % | -38.6 % | −52.7 % | -14.6 % | 83 | 64 | 7.0 % | 9.3 % | 2.44 | — | 2.2 | 0.1 | — | 1.7 | 0.15 | 25.2 | — | 28.9 % | -14.1 % | -115.4 % | 0.2 % | — | — | +12.9 % | 3.6 % | 94.3 % | 4.3 | 69.9 % | 32.5 % | — |
| PSNL Personalis Inc | 08/04 | +136 % | 30 3/22 | Stage 2 | D -39 | 3 of 9 | 1.3 | Diagnostics & Research | – | — | — | Healthcare | 13.30 $ | +26.4 % | +63.5 % | +82.9 % | −2.2 % | -13.8 % | 82 | 42 | 10.2 % | 10.2 % | 2.24 | — | 0.0 | 20.4 | — | — | — | 0.0 | — | 13.7 % | -148.1 % | -41.4 % | -21.4 % | — | — | -17.7 % | 0.0 % | 0.0 % | 2.9 | 68.2 % | 16.8 % | — |
| IPGP IPG Photonics Corporation | 08/04 | -6 % | 80 8/25 | Stage 2 | C +7 | 3 of 9 | 5.1 | Semiconductor Equipment & Ma | – | — | — | Technology | 97.90 $ | +50.3 % | +48.5 % | +59.8 % | −29.3 % | +18.4 % | 68 | 13 | 5.8 % | 6.6 % | 0.94 | 157.6 | 69.9 | 4.9 | 2.2 | — | 1.83 | 40.0 | 2.1 % | 37.6 % | 2.8 % | 1.4 % | 0.6 % | 0.01 | 87.4 % | +2.7 % | 0.0 % | 0.0 % | 17.4 | 71.8 % | 17.1 % | 2.0 (9) |
| UTI Universal Technical Institute Inc | 08/05 | +163 % | 98 8/16 | Stage 2 | C -10 | 4 of 9 | 2.2 | Education & Training Service | – | — | — | Consumer Defensive | 37.90 $ | +52.1 % | +51.7 % | +13.3 % | −12.5 % | +9.1 % | 67 | 2 | 4.6 % | 5.8 % | 1.23 | 54.7 | 55.6 | 2.5 | 6.7 | 1,230.6 | 3.70 | 23.2 | 0.2 % | 55.5 % | 4.9 % | 13.5 % | 4.4 % | 0.93 | 39.9 % | +14.1 % | 0.0 % | 0.0 % | 5.1 | 99.2 % | 9.5 % | 1.0 (6) |
| SG Sweetgreen Inc | 08/06 | -8 % | 74 9/31 | Stage 2 | C +3 | 4 of 9 | 1.1 | Restaurants | Uses AI | — | Consumer Cyclical | 6.70 $ | +22.6 % | +21.8 % | -30.6 % | −46.4 % | -10.8 % | 62 | 42 | 6.9 % | 9.2 % | 2.18 | 76.2 | 18.2 | 1.6 | 2.2 | — | — | 13.8 | — | 14.4 % | 2.5 % | 3.6 % | -9.2 % | 0.73 | — | +0.4 % | 0.0 % | 0.0 % | 1.9 | 84.2 % | 22.3 % | — | |
| CSL Carlisle Companies Incorporated | 07/29 | +17 % | 9 2/29 | Stage 2 | D -15 | 4 of 9 | 15.7 | Building Products & Equipmen | – | — | — | Industrials | 327.30 $ | +11.0 % | +14.5 % | +5.2 % | −10.9 % | +5.6 % | 40 | 30 | 5.2 % | 3.9 % | 0.85 | 22.7 | 17.5 | 3.2 | 9.5 | 17.0 | 1.17 | 13.8 | 17.4 % | 35.6 % | 14.6 % | 38.2 % | 10.9 % | 24.86 | 27.6 % | +0.3 % | 1.2 % | 22.7 % | 10.4 | 103.8 % | 8.5 % | 1.4 (7) |
| ESAB ESAB Corp | 08/05 | +18 % | 9 2/29 | Stage 4 | C -5 | 3 of 9 | 6.2 | Metal Fabrication | – | — | — | Industrials | 83.00 $ | -13.4 % | -13.9 % | -17.3 % | −28.1 % | +37.0 % | 25 | 20 | 5.7 % | 4.8 % | 1.14 | 25.9 | 15.8 | 2.1 | 2.7 | 28.3 | 1.26 | 14.3 | 13.5 % | 36.7 % | 7.1 % | 11.4 % | 5.8 % | 0.98 | 39.0 % | +3.7 % | 0.5 % | 8.5 % | 6.6 | 99.8 % | 7.2 % | 1.5 (11) |
| FND Floor & Decor Holdings Inc | 07/30 | -16 % | 3 1/31 | Stage 4 | C -6 | 4 of 9 | 6.4 | Home Improvement Retail | – | — | — | Consumer Cyclical | 53.90 $ | -15.5 % | -7.4 % | -24.7 % | −36.9 % | -7.6 % | 16 | 24 | 5.6 % | 5.4 % | 1.58 | 31.9 | 25.7 | 1.4 | 2.5 | 60.3 | 2.20 | 15.9 | 4.6 % | 45.0 % | 4.3 % | 8.5 % | 2.9 % | 0.82 | 44.1 % | +5.1 % | 0.0 % | 0.0 % | 5.7 | 118.2 % | 12.7 % | 1.8 (24) |
| CRVO CervoMed Inc. | 08/14 | -28 % | 16 2/22 | Stage 4 | D -50 | 1 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 2.80 $ | -52.9 % | -79.6 % | -50.0 % | −74.5 % | +482.1 % | 8 | 42 | 21.8 % | 12.8 % | -4.42 | — | 0.0 | 12.9 | 3.0 | — | — | 1.6 | — | -958.5 % | 0.0 % | -132.8 % | -72.4 % | — | — | -58.9 % | 0.0 % | 0.0 % | -18.8 | 13.3 % | 5.4 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Donnelly's sell/risk side (lifecycle trade approach): stocks with at least $20M in daily dollar volume that are down at least 5% today. When stocks sell off on this much liquidity, institutions are heading for the exit — a warning sign for holders, and for Donnelly the trigger to review exit rules. Mover threshold calibrated by Minnow Street.
All scanners are recalculated daily across the entire stock universe — most recently on 21. July 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 18 stocks pass this scanner's criteria (as of 21. July 2026).
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Altman Z: Distress Zone
- Below the 50- & 200-SMA
- Beneish M-Score
- Downward Momentum
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- Mike Webster: Overextended (Webby RSI)
- Near 52-Week Low
- Pradeep Bonde: $ Breakout Bearish
- Pradeep Bonde: 4% Breakout Bearish
- Qullamaggie: Parabolic (Short-Watch)
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Insolvency Candidate
- Weakness Cluster
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.